Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Millennium Management Llc Acquires 9,533 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc purchased 9,533 shares of the firm’s stock in a transaction on Monday, March 30th. The shares were acquired at an average price of $25.86 per share, for a total transaction of $246,523.38. Following the purchase, the insider directly owned 145,678 shares of the company’s stock, valued at approximately $3,767,233.08. This represents a 7.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total transaction of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total transaction of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total transaction of $23,629.68.
• On Friday, March 27th, Millennium Management Llc bought 15,321 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $26.61 per share, for a total transaction of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc bought 5,731 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $28.62 per share, for a total transaction of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total value of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc purchased 6,175 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $34.49 per share, with a total value of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc purchased 6,005 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $28.16 per share, with a total value of $169,100.80.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $32.12, for a total value of $246,231.92.

Sensei Biotherapeutics Trading Up 3.1%

Shares of Sensei Biotherapeutics stock traded up $0.61 during trading on Friday, reaching $20.43. The company’s stock had a trading volume of 40,084 shares, compared to its average volume of 223,112. The stock has a 50-day moving average price of $29.11 and a two-hundred day moving average price of $17.85. Sensei Biotherapeutics, Inc. has a one year low of $5.25 and a one year high of $36.76. The stock has a market capitalization of $27.40 million, a P/E ratio of -1.23 and a beta of -0.18.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($130.83). As a group, sell-side analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics News Roundup

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on SNSE shares. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Finally, Leerink Partners started coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price target for the company. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.